Benefits of the novel use of a compounded oral suspension in chemotherapy and radiotherapy induced mucositis

• Autores: Mireya Mañes Sevilla, Eva González-Haba Peña, B. Marzal Alfaro, Roberto Collado Borrell, Ana Herranz Alonso, María Sanjurjo Sáez
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 19, Nº. 3, 2017, págs. 185-189
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose: To identify the onco-hematological patients who can be benefit of the compounded oral suspension for mucositis (COSM), developed by the Pharmacy Department, and describe its using profile in hospitalized patient. Method: This observational, descriptive, retrospective, cohort study included onco-hematological patients who presented mucositis and were treated with the COSM. Electronic prescriptions were used to collect the data: patients' characteristics, clinical variables; reason for the appearance; drugs involved; therapy of the COSM; tolerance; additional topical treatment; analgesic and anti-micro- bial treatment; nutritional support and date of mucositis resolution. Results: Seventy patients were included. The most common diagnoses were: Acute myeloid leukemia and head and neck cancer. The severity of mucositis was mainly grade I. Mucositis was related to chemotherapy treatment in 73% of the patients. Radiotherapy treatment caused mucositis in 27% of the patients. All the patients had a good tolerance to the suspension. Sixty-Three patients received analgesic treatment during the hospitalization and twenty-Three patients required morphine. Seven patients required parenteral nutrition support during hospital admission, however it was discontinued, in all patients, before the hospital discharge. Also twenty-five patients needed antimicrobials for the prevention of fungal infections. In 50% of the patients mucositis was resolved by the 8th day (IQR: 14-3). Conclusion: Our study demonstrated that the COSM is widely and effectively used in chemotherapy and radiotherapy-Treated patients. Despite establishing a systemic treatment, the suspension has been maintained to sooth pain. In addition, our study suggests that only 10% of patients needed parenteral nutrition support. Our mouthwash could have minimized the required nutritional support